Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. inge is advising Xspray Pharma in connection with its rights issue
Mandate

Vinge is advising Xspray Pharma in connection with its rights issue

December 03, 2024 Capital Markets and Public M&A

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of shares whereby Xspray receives issue proceeds of approximately SEK 135 million before deduction of transaction costs.

Xspray is a pharmaceutical company that specializes in using its patented HyNap-technology to develop improved versions of existing protein kinase inhibitors (PKIs) for cancer treatment. The company's goal is to become a leader in the development of improved PKIs for cancer treatment. Xspray’s shares are listed on Nasdaq Stockholm.

Vinge’s team primarily consisted of Dain Hård Nevonen, Joel Magnusson, Adrian Filipovic and Elias Kröger.

Related

Vinge has represented Eleda in connection with the acquisitions of Marbit Aktiebolag, FlexiRail AB, and Hanell Entreprenad i Gävle AB

 Vinge has represented the leading infrastructure group Eleda in connection with the acquisitions of Marbit Aktiebolag, FlexiRail AB, and Hanell Entreprenad i Gävle AB from Vestum. These companies are engaged in contracting activities within the construction sector. The total purchase price for the shares amounts to 747 MSEK. All key executives in the companies will become shareholders in Eleda.
December 02, 2024

Vinge has advised Fortum in connection with the divestment of its recycling and waste business

 Vinge, alongside among others Castrén & Snellman, has advised Fortum in connection with the divestment of its recycling and waste business to Summa Equity through its portfolio company NG Group. The debt free purchase price is approximately EUR 800 million.
December 02, 2024

Vinge advises Active Biotech in connection with rights issue

 Vinge advises Active Biotech AB (publ) in connection with a rights issue of approximately SEK 43 million.
November 29, 2024